Drug intelligence / Profile preview

KH-629

Development stage: Unknown
Lead developer: Chengdu Kanghong Pharmaceutical
Modality: Small Molecules

Overview

KH-629 is a small molecule drug developed by Chengdu Kanghong Pharmaceutical Group. It acts as an agonist of the thyroid hormone receptor beta (THR-β). The primary mechanism of action is selective activation of THR-β, which plays a key role in regulating lipid metabolism and liver function. KH-629 is being investigated for the treatment of nonalcoholic steatohepatitis (NASH), a progressive liver disease characterized by fat accumulation, inflammation, and fibrosis in the liver[1].

Targets

THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on KH-629.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KH-629.

Explore the full profile